Premium
Baicalein exerts neuroprotective effects in 6‐hydroxydopamine induced experimental Parkisonism (LB625)
Author(s) -
Mu Xin,
Lu Yang,
Du Guanhua
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.lb625
Subject(s) - baicalein , neuroprotection , pharmacology , substantia nigra , chemistry , glial fibrillary acidic protein , antioxidant , hydroxydopamine , medicine , dopamine , biochemistry , immunohistochemistry , dopaminergic
Baicalein, a flavonoid with potent antioxidant and anti‐inflammatory properties, has been shown to have neuroprotective effects. But baicalein has a pool dissolvability and scarcely dissolve in water. Thus,our topic group studied the crystal form of the chemical composition of baicalein. The result showed that baicalein possessed polymorphism. Moreover, β crystal form of baicalein was determined to be a superiority drug crystal because of its dominant position in stability and absorbance by constancy and biological test. So β crystal form of baicalein was used in this experiment. In rats, the behavioral and immunohistochemical manifestations after unilateral 6‐OHDA lesion were determined. Baicalein could significantly attenuate muscle tremor of 6‐OHDA lesioned rats (the burst frequency and amplitude are 13.43%, 35.18% compared to 6‐OHDA group), but could not reduce apomorphine (APO)‐induced rotations. Moreover, baicalein treatment could also increase tyrosine hydroxylase (TH)‐positive neurons (265.52% compared to 6‐OHDA group) and ameliorate the severe increase of glial fibrillary acidic protein (GFAP) immunoreactivity (70.23% compared to 6‐OHDA group) in the substantia nigra. Therefore, baicalein can be a promising candidate for prevention or treatment of Parkinson’s disease, owing to its anti‐apoptotic, pro‐differentiation and anti‐inflammatory action. Grant Funding Source : This work was supported by the Research Special Fund for Public Welfare Industry of Health (No. 200802041) and National Significant Projects of New Drugs Creation (No. 2009ZM09501‐021).